Advertisement

Protection by a Recombinant DNA Vaccine Against Hepatitis B, Preliminary Report

  • C. Goilav
  • H. Prinsen
  • A. Safary
  • F. E. André
  • P. Piot

Abstract

Between April 1985 and March 1986, 314 gay men, aged 18–64 years, all negative for hepatitis B (HBV) infection, were enrolled into a clinical study to evaluate the immune response and to estimate the protection given by a recombinant DNA vaccine against HBV (Engerix-B, SmithKline Biologicals, Rixen-sart, Belgium) in a high-risk group. At this time, the vaccine schedule was three doses at months 0, 1 and 6 intramuscularly (deltoid region). Boosters were given if the serum level of anti-HBs was below 100 IU/liter in the follow-up period. Control samples were taken at months − 1,1, 3,6, 7,12 and 24. Symptom sheets were collected after each injection. Two doses of vaccine were tested (20 or 40 µg). In the groups available for analysis the seroconversion rate for anti-HBs at month 7 was 98% in both dose ranges and the geometric mean titers (GMTs) of anti-HBs were 1027 (n= 131) and 2363 IU/liter (n = 66) respectively. The seroconversion rates and persistence are shown in Table I. Some candidates had a spontaneous rise of their anti-HBs levels (with more

Keywords

Vaccine Dose Seroconversion Rate Homosexual Male Number Number Frequent Side Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Springer-Verlag Berlin Heidelberg 1989

Authors and Affiliations

  • C. Goilav
  • H. Prinsen
  • A. Safary
  • F. E. André
  • P. Piot

There are no affiliations available

Personalised recommendations